Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
Sharma A, Pagidipati NJ, Califf RM, McGuire DK, Green JB, Demets D, George JT, Gerstein HC, Hobbs T, Holman RR, Lawson FC, Leiter LA, Pfeffer MA, Reusch J, Riesmeyer JS, Roe MT, Rosenberg Y, Temple R, Wiviott S, McMurray J, Granger C. Sharma A, et al. Among authors: riesmeyer js. Circulation. 2020 Mar 10;141(10):843-862. doi: 10.1161/CIRCULATIONAHA.119.041022. Epub 2020 Jan 29. Circulation. 2020. PMID: 31992065
Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.
Boye KS, Riddle MC, Gerstein HC, Mody R, Garcia-Perez LE, Karanikas CA, Lage MJ, Riesmeyer JS, Lakshmanan MC. Boye KS, et al. Among authors: riesmeyer js. Diabetes Obes Metab. 2019 Jun;21(6):1299-1304. doi: 10.1111/dom.13649. Epub 2019 Mar 12. Diabetes Obes Metab. 2019. PMID: 30714309 Free PMC article.
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.
Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE; ACCELERATE Investigators. Lincoff AM, et al. Among authors: riesmeyer js. N Engl J Med. 2017 May 18;376(20):1933-1942. doi: 10.1056/NEJMoa1609581. N Engl J Med. 2017. PMID: 28514624 Free article. Clinical Trial.
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Among authors: riesmeyer js. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189511 Clinical Trial.
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.
Povsic TJ, Scott R, Mahaffey KW, Blaustein R, Edelberg JM, Lefkowitz MP, Solomon SD, Fox JC, Healy KE, Khakoo AY, Losordo DW, Malik FI, Monia BP, Montgomery RL, Riesmeyer J, Schwartz GG, Zelenkofske SL, Wu JC, Wasserman SM, Roe MT. Povsic TJ, et al. Cardiovasc Drugs Ther. 2017 Aug;31(4):445-458. doi: 10.1007/s10557-017-6739-9. Cardiovasc Drugs Ther. 2017. PMID: 28735360 Review.
Designing, Conducting, Monitoring, and Analyzing Data from Pragmatic Randomized Clinical Trials: Proceedings from a Multi-stakeholder Think Tank Meeting.
Lentz TA, Curtis LH, Rockhold FW, Martin D, Andersson TLG, Arias C, Berlin JA, Binns C, Cook A, Cziraky M, Dent R, Desai M, Emmett A, Esserman D, George J, Hantel S, Heagerty P, Hernandez AF, Hucko T, Khan N, Lee SF, LoCasale R, Mardekian J, McCall D, Monda K, Normand SL, Riesmeyer J, Roe M, Roessig L, Scott R, Siedentop H, Waldstreicher J, Wang L, Weerakkody G, Wolf M, Ellenberg SS. Lentz TA, et al. Ther Innov Regul Sci. 2020 Nov;54(6):1477-1488. doi: 10.1007/s43441-020-00175-7. Epub 2020 Jun 8. Ther Innov Regul Sci. 2020. PMID: 32514736
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E; TRITON-TIMI 38 Investigators. Wiviott SD, et al. Am Heart J. 2006 Oct;152(4):627-35. doi: 10.1016/j.ahj.2006.04.012. Am Heart J. 2006. PMID: 16996826 Clinical Trial.
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Wiviott SD, et al. N Engl J Med. 2007 Nov 15;357(20):2001-15. doi: 10.1056/NEJMoa0706482. Epub 2007 Nov 4. N Engl J Med. 2007. PMID: 17982182 Free article. Clinical Trial.
Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy.
Menon V, Kumar A, Patel DR, John JS, Wolski KE, McErlean E, Riesmeyer JS, Weerakkody G, Ruotolo G, Cremer PC, Nicholls SJ, Lincoff AM, Nissen SE. Menon V, et al. Among authors: riesmeyer js. J Am Heart Assoc. 2020 Jan 7;9(1):e014328. doi: 10.1161/JAHA.119.014328. Epub 2019 Dec 19. J Am Heart Assoc. 2020. PMID: 31852422 Free PMC article. Clinical Trial.
30 results